Chronic liver disease is a progressive decline in liver function lasting more than six months. It affects roughly 1.7 billion people worldwide and caused about 1.4 million deaths in 2021 alone. The term covers a wide spectrum, from early fatty buildup in liver tissue all the way to cirrhosis, where the liver’s internal structure is permanently distorted by scar tissue.
How the Liver Becomes Damaged Over Time
Your liver can absorb a surprising amount of damage before you notice anything wrong. When an injury is ongoing, whether from alcohol, a virus, or excess fat, the liver’s repair process starts to work against it. Inflammation triggers specialized cells in the liver to transform into a type that produces scar tissue. These cells keep laying down fibrous material as long as the injury continues, gradually replacing healthy liver tissue.
This scarring process is called fibrosis, and it happens in stages. Doctors score it on a scale from F0 (no fibrosis) to F4 (cirrhosis). In the earlier stages (F1 through F3), scar tissue forms around the liver’s internal blood vessels and begins creating bridges between them. At F4, the scarring is extensive enough to distort the liver’s architecture, forming nodules of regenerating tissue surrounded by bands of scar. This is cirrhosis, and it fundamentally changes how blood flows through the organ.
The important thing to understand: stages F1 through F3 are generally reversible if the underlying cause is removed. Even early cirrhosis can partially reverse in some cases. One large analysis found that cirrhosis regression was associated with a six-fold reduction in serious liver complications.
Leading Causes
Three categories account for the vast majority of chronic liver disease globally: fatty liver disease tied to metabolic problems, viral hepatitis, and alcohol.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease or NAFLD, is now the most common chronic liver disease in the world. It affects about 38% of the global adult population. The name was officially changed in 2023 to better reflect the disease’s metabolic roots and to move away from language the medical community considered stigmatizing. MASLD develops when fat accumulates in the liver alongside at least one metabolic risk factor like obesity, type 2 diabetes, or high blood pressure. In some people, this fat buildup triggers inflammation and more aggressive scarring, a condition now called MASH (formerly NASH).
Hepatitis B and C viruses remain major drivers, particularly in low-income countries. Together, they cause around 1.3 million deaths per year. Hepatitis C is now curable with antiviral treatment, and hepatitis B can be suppressed long-term with medication, but many people remain undiagnosed.
Alcohol-related liver disease follows a predictable path: fatty liver first, then inflammation (alcoholic hepatitis), then cirrhosis. The fatty liver stage is reversible with abstinence. Once cirrhosis sets in, the structural damage is not.
What It Feels Like at Each Stage
Early chronic liver disease is notoriously silent. Most people with fibrosis stages F1 or F2 have no symptoms at all. You might feel generally fatigued or notice mild discomfort in the upper right side of your abdomen, but many people feel nothing.
Symptoms typically appear once the disease reaches cirrhosis, and they get significantly worse when the liver can no longer compensate for the damage. This shift from “compensated” to “decompensated” cirrhosis marks a critical turning point. Decompensated cirrhosis brings a set of complications driven largely by portal hypertension, a condition where blood pressure builds in the veins feeding the liver because scar tissue blocks normal flow. The signs include:
- Ascites: fluid leaking from swollen veins into the abdomen, causing bloating, rapid weight gain, and sometimes difficulty breathing
- Variceal bleeding: enlarged veins in the esophagus or stomach that can rupture, showing up as blood in vomit or stool
- Hepatic encephalopathy: mental confusion, disorientation, or personality changes caused by toxins the liver can no longer filter
- Edema: swelling in the legs and feet
These complications often appear before someone even knows they have liver disease. Blood in vomit, sudden abdominal swelling, or unexplained confusion can be the first indication of a problem that has been building for years.
How It’s Detected
Because chronic liver disease is usually symptomless in its early stages, detection often relies on blood tests and imaging rather than reported symptoms.
Liver enzymes (AST and ALT) are the most common initial screening tool. When both are elevated, it signals liver cell damage. The ratio between the two can help estimate severity: as liver function worsens, the AST-to-ALT ratio tends to climb. A low platelet count and changes in blood clotting speed also point toward advancing disease.
To measure how much scarring is present without a biopsy, many doctors now use a specialized ultrasound called transient elastography. This measures liver stiffness in kilopascals (kPa). A reading below about 7 kPa is generally normal. Readings above 7.2 kPa suggest moderate fibrosis, above 12.5 kPa suggest severe fibrosis, and readings above 17.6 kPa indicate cirrhosis. The test takes about 10 minutes and feels like a standard ultrasound.
Liver biopsy, where a small tissue sample is taken with a needle, remains the most precise way to assess fibrosis stage but is used less frequently now that non-invasive options are available.
Slowing or Reversing the Damage
Treatment depends entirely on the cause, but one principle applies across the board: removing or controlling the source of injury gives the liver a chance to heal. The liver has a remarkable capacity for regeneration, and fibrosis can reverse even at advanced stages if the trigger is eliminated early enough.
For MASLD and MASH, weight loss is the most effective intervention. Losing 3% to 5% of body weight improves fat buildup in the liver, but more substantial weight loss (over 10%) is generally needed to reverse inflammation and fibrosis. Bariatric surgery, in patients who qualify, has shown particularly strong results. One long-term study found that 80% of patients had resolution of liver inflammation one year after surgery, with benefits sustained at five years.
For hepatitis-related liver disease, antiviral treatment can halt or reverse fibrosis by eliminating the virus (hepatitis C) or suppressing it (hepatitis B). For alcohol-related disease, stopping alcohol use is the single most important step.
Nutrition in Chronic Liver Disease
Malnutrition is a common and underappreciated problem in chronic liver disease, especially in cirrhosis. The damaged liver struggles to process and store nutrients normally, which means your body’s protein and energy needs actually increase even as appetite often decreases.
People with chronic liver disease are recommended to eat 1.2 to 1.5 grams of protein per kilogram of body weight per day, roughly 1.5 times more than a healthy adult needs. For someone with cirrhosis, that recommendation can go as high as 1.8 grams per kilogram. Falling below 1.0 gram per kilogram is a risk factor for malnutrition, which worsens outcomes significantly. Eating smaller, more frequent meals and including a late-evening snack that contains protein can help prevent the overnight fasting that accelerates muscle loss in liver disease.
Rising Rates in Younger Adults
Chronic liver disease is becoming more common, not less. Global incidence rates have been climbing steadily since 1990, with the sharpest increases among adults aged 15 to 49. MASLD has driven much of this rise, reflecting global trends in obesity, diabetes, and sedentary lifestyles. Europe and the Americas have seen the fastest growth in new cases.
Death rates from chronic liver disease have actually declined overall, likely due to better treatments for hepatitis and improved management of cirrhosis complications. But this improvement has not been evenly distributed. Low-income countries carry a disproportionately heavy burden of liver disease deaths, a gap that has widened over the past three decades. Projections through 2050 suggest new cases will continue to rise while death rates continue to fall, meaning more people will be living with chronic liver disease for longer periods.